KIP2 Antikörper (CF®568)

Produktnummer ABIN7656300

Der CF®568-konjugierte Maus Monoklonal anti-KIP2 Antikörper (Klon 57P06) (ABIN7656300) detektiert spezifisch KIP2 in IHC und IHC (fp). Dieser Antikörper reagiert spezifisch mit Proben aus Human und Maus.

Kurzübersicht für KIP2 Antikörper (CF®568) (ABIN7656300)

Target: KIP2

Reaktivität: Human, Maus

Wirt: Maus

Klonalität: Monoklonal

Konjugat: CF®568

Applikation: Immunohistochemistry (IHC), Immunohistochemistry (Formalin-fixed Paraffin-embedded Sections) (IHC (fp))

Klon: 57P06

Produktdetails

Verwendungszweck: p57Kip2 (Mitotic Inhibitor/Suppressor Protein)(57P06), CF568 conjugate

Produktmerkmale: Recognizes a protein of 57 kDa, identified as p57Kip2. It shows no cross-reaction with p27Kip1. p57Kip2 is a potent tight-binding inhibitor of several G1 cyclin complexes, and is a negative regulator of cell proliferation. Anti-p57 has been used as an aide in identification of complete hydatidiform mole (CHM) (no nuclear labeling of cytotrophoblasts and stromal cells) from partial hydatidiform mole (PHM) in which both cytotrophoblasts and stromal cells stain. The histological differentiation of complete mole, partial mole, and hydropic spontaneous abortion is problematic. Most complete hydatidiform moles are diploid, whereas most partial moles are triploid. Ploidy studies will identify partial moles, but will not differentiate complete moles from non-molar gestations. Complete moles carry a high risk of persistent disease and choriocarcinoma, while partial moles have a very low risk. In normal placenta, many cytotrophoblast nuclei and stromal cells are labeled with this antibody. Similar findings apply to PHM and hydropic abortus tissues. Intervillous trophoblastic islands (IVTIs) demonstrate nuclear labeling in all three entities and serve as an internal control.

Immunogen: Recombinant full-length human p57Kip2 protein

Isotyp: IgG2b, kappa

Anwendungsinformationen

Applikationshinweise: Higher concentration may be required for direct detection using primary antibody conjugates than for indirect detection with secondary antibody. Immunohistochemistry (formalin-fixed): 0.25-0.5 μg/mL for 30 minutes at RT. Flow cytometry: 0.5-1 μg/million cells. Immunofluorescence: 0.5-1 μg/mL. Staining of formalin-fixed tissues requires boiling tissue sections in 10 mM citrate buffer, pH 6.0, for 10-20 minutes followed by cooling at RT for 20 minutes. Optimal dilution for a specific application should be determined by user

Kommentare:

Positive Control: LS174T, Raji, HT29, SK-BR3 cells. Colon or Prostate carcinomas.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 0.1 mg/mL

Buffer: PBS, 0.1 % BSA, 0.05 % azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Protect from light

Lagerung: 4 °C

Informationen zur Lagerung:

Stable at room temperature or 37°C for 7 days.

Protect from light

Store at 2 to 8°C. Protect fluorescent conjugates from light

Haltbarkeit: 24 months

Antigendetails

Target: KIP2

Hintergrund:

Synonyms: Beckwith Wiedemann syndrome (WBS), BWCR, Cyclin dependent kinase inhibitor 1C (CDKN1C), KIP2, p57

Gene Symbol: CDKN1C

Molekulargewicht: 57 kDa

Gen-ID: 1028

UniProt: P49918